These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1157 related articles for article (PubMed ID: 34742583)

  • 1. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
    Cathomas R; Lorch A; Bruins HM; Compérat EM; Cowan NC; Efstathiou JA; Fietkau R; Gakis G; Hernández V; Espinós EL; Neuzillet Y; Ribal MJ; Rouanne M; Thalmann GN; van der Heijden AG; Veskimäe E; Alfred Witjes J; Milowsky MI;
    Eur Urol; 2022 Jan; 81(1):95-103. PubMed ID: 34742583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
    Witjes JA; Bruins HM; Cathomas R; Compérat EM; Cowan NC; Gakis G; Hernández V; Linares Espinós E; Lorch A; Neuzillet Y; Rouanne M; Thalmann GN; Veskimäe E; Ribal MJ; van der Heijden AG
    Eur Urol; 2021 Jan; 79(1):82-104. PubMed ID: 32360052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
    Rouprêt M; Seisen T; Birtle AJ; Capoun O; Compérat EM; Dominguez-Escrig JL; Gürses Andersson I; Liedberg F; Mariappan P; Hugh Mostafid A; Pradere B; van Rhijn BWG; Shariat SF; Rai BP; Soria F; Soukup V; Wood RG; Xylinas EN; Masson-Lecomte A; Gontero P
    Eur Urol; 2023 Jul; 84(1):49-64. PubMed ID: 36967359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
    Alfred Witjes J; Max Bruins H; Carrión A; Cathomas R; Compérat E; Efstathiou JA; Fietkau R; Gakis G; Lorch A; Martini A; Mertens LS; Meijer RP; Milowsky MI; Neuzillet Y; Panebianco V; Redlef J; Rink M; Rouanne M; Thalmann GN; Sæbjørnsen S; Veskimäe E; van der Heijden AG
    Eur Urol; 2024 Jan; 85(1):17-31. PubMed ID: 37858453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors].
    Casuscelli J; von Amsberg G; Retz M
    Urologie; 2024 Oct; 63(10):1002-1010. PubMed ID: 39235511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
    Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    Wei XX; Werner L; Teo MY; Rosenberg JE; Koshkin VS; Grivas P; Szabados B; Morrison L; Powles T; Carril-Ajuria L; Castellano D; Velho PI; Hahn NM; McKay RR; Raggi D; Necchi A; Kanesvaran R; Alerasool P; Gaines J; Galsky M; Bellmunt J; Sonpavde G
    J Urol; 2021 Feb; 205(2):414-419. PubMed ID: 32935617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Gupta S; Moon HH; Sridhar SS
    Target Oncol; 2024 Jul; 19(4):483-494. PubMed ID: 38963655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?
    Audisio M; Tucci M; Di Stefano RF; Parlagreco E; Ungaro A; Turco F; Audisio A; Di Prima L; Ortega C; Di Maio M; Scagliotti GV; Buttigliero C
    Crit Rev Oncol Hematol; 2022 Jun; 174():103682. PubMed ID: 35421529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
    Rouprêt M; Babjuk M; Compérat E; Zigeuner R; Sylvester RJ; Burger M; Cowan NC; Böhle A; Van Rhijn BW; Kaasinen E; Palou J; Shariat SF
    Eur Urol; 2015 Nov; 68(5):868-79. PubMed ID: 26188393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving treatment landscape of metastatic urothelial cancer.
    Roviello G; Santoni M; Sonpavde GP; Catalano M
    Nat Rev Urol; 2024 Oct; 21(10):580-592. PubMed ID: 38702396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in systemic therapy for advanced-stage urothelial carcinoma.
    Nadal R; Valderrama BP; Bellmunt J
    Nat Rev Clin Oncol; 2024 Jan; 21(1):8-27. PubMed ID: 37945764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Loriot Y; Matsubara N; Park SH; Huddart RA; Burgess EF; Houede N; Banek S; Guadalupi V; Ku JH; Valderrama BP; Tran B; Triantos S; Kean Y; Akapame S; Deprince K; Mukhopadhyay S; Stone NL; Siefker-Radtke AO;
    N Engl J Med; 2023 Nov; 389(21):1961-1971. PubMed ID: 37870920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates and novel treatments in urothelial carcinoma.
    Hanna KS
    J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.